F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES for F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Issues related to government purchases and stockpiling of pandemic drugs (tamiflu); health pandemic flu funding and emergency preparedness;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director, Federal Government Affairs |
Health Issues HCR
Pandemic preparedness; accutane safety; general diabetes and pharmaceutical issues; health care reform legislation; H.R. 3200, America Affordable Health Choices Act; and the America's Health Future Act of 2009; Community Relations and Outreach to develop and maintain relationships with minority groups and health organizations to promote diabetes awareness. Developing strategies on the most effective approaches to address and try to resolve health disparities affecting minority communities General healthcare issues - biosimilars.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN A CLAESSENS | Director, Roche Diagnostics |
| DARIN GARDNER | Director, Federal Government Affairs |
| ANNA GRIFFIN | Director, Federal Government Affairs |
| KATHERINE MARTIN | Director, Federal Government Affairs |
| EVAN MORRIS | Vice President, Government Affairs |
Medicare/Medicaid MMM
Reimbursement and other issues related to arthritis drugs; H.R. 3200 America's Affordable Health Choices Act and the Americas Healthy Future Act of 2009 and issues pertaining to Medicare drug pricing and biosimilars; and general health care reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director, Federal Government Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.